ThermEval's objective is to significantly reduce the incidence of heart attacks, strokes and thyroid disorders with widespread ACT Examination screenings. Our vision is improved patient mortality and reduced public cost of dealing with these health issues.
Heart attacks, strokes and thyroid disorders are secondary complications of coronary artery atherosclerosis, carotid stenosis, and thyroid dysfunction. These clinical symptoms are three of the four leading causes of death for those 65 and over.
The first wave of the 76-million Baby Boomers turned 65 in 2011. The expected dramatic increase in afflicted older patients has begun, and with it, increased public cost. Medicare projects that by 2020 the cost of treating the clinical complications of these diseases will soar to $400 billion, or forty-percent of Medicare's $1 trillion estimated total cost.
Many clinical episodes may be avoided if their underlying disease is detected and treated early enough. Regrettably, the high cost of comprehensive screening is not covered by Medicare, except for high risk or clinically symptomatic patients. This financial burden is typically deferred by the patient...until a sudden catastrophe strikes.
Many patients are unaware they may be at serious risk and in need of treatment to thwart potential disaster. These 'hidden risks' belong to those at elevated risk, but not categorized high risk by their 'Welcome to Medicare' preventative screening.
For $225, about 5% of the cost of comprehensive screenings, the ACT Examination answers the question, 'Am I demonstrably at elevated risk and needing further (covered) comprehensive screening?'
We're confident that widespread ACT Examination screenings will reveal symptoms of the underlying diseases while they are still subclinical. Treating these diseases will improve patient mortality and reduce long-term public cost.